Advertisement
Table 1 Demographic and clinical data of the study population
| Healthy | Allrg Rhin | Asm NoEx | Asm Ex | Total | |
|---|---|---|---|---|---|
| Participants, n (%) | 9 (18.0) | 7 (14.0) | 23 (46.0) | 11 (22.0)a | 50 (100.0) |
| Female, n (%) | 7 (14.0) | 3 (6.0) | 18 (36.0) | 10 (20.0) | 38 (76.8) |
| Age; median years (max-min) | 30 (18 to 37) | 31 (20 to 47) | 37 (19 to 66) | 29 (25 to 46) | 32 (18 to 66) |
| Ethnicity, n (%) | |||||
| White | 8 (16.0) | 5 (10.0) | 13 (26.0) | 9 (18.0) | 35 (70.0) |
| African American | 0 (0.0) | 1 (2.0) | 4 (8.0) | 1 (2.0) | 6 (12.0) |
| Hispanic | 0 (0.0) | 0 (0.0) | 3 (6.0) | 0 (0.0) | 3 (6.0) |
| Other | 1 (2.0) | 1 (2.0) | 3 (6.0) | 1 (2.0) | 6 (12.0) |
| Atopic, n (%) | 1 (2.0) | 7 (14.0) | 18 (36.0) | 8 (16.0) | 34 (68.0) |
| Baseline PC 20 ; mean mg/mL (±SD) | 28 (27.1) | 6.7 (3.8) | 4.5 (5.1) | 4.4 (5.2) | n/a |
| Baseline FEV1; mean% predicted (±SD) | 98.3 (11.0) | 105.8 (6.7) | 97.8 (16.5) | 91.2 (10.8) | n/a |
| Medication, n (%) | |||||
| Inhaled corticosteroids | 0 (0.0) | 0 (0.0) | 6 (12.0) | 3 (6.0) | 9 (18.0) |
| Inhaled corticosteroids plus long-acting beta agonists | 0 (0.0) | 0 (0.0) | 2 (4.0) | 1 (2.0) | 3 (6.0) |
| Nasal steroids | 0 (0.0) | 0 (0.0) | 6 (12.0) | 3 (6.0) | 9 (18.0) |
| Respiratory virus identification, n (%) | |||||
| Human rhinovirus | 5 (10.0) | 1 (2.0) | 9 (18.0) | 3 (6.0) | 18 (36.0) |
| Respiratory syncytial virus | 0 (0.0) | 0 (0.0) | 2 (4.0) | 1 (2.0)b | 3 (6.0) |
| Human coronavirus | 1 (2.0) | 1 (2.0) | 2 (4.0) | 2 (4.0)b | 6 (12.0) |
| Influenza A virus | 0 (0.0) | 1 (2.0) | 1 (2.0) | 0 (0.0) | 2 (4.0) |
| Human parainfluenza virus | 0 (0.0) | 1 (2.0) | 0 (0.0) | 0 (0.0) | 1 (2.0) |
| No detection | 3 (6.0) | 3 (6.0) | 9 (18.0) | 5 (10.0) | 20 (40.0) |
